目的:观察以致康胶囊为基础配合西药治疗幽门螺杆菌(Hp)的疗效、不良反应和药品费用,以探讨临床较佳的改善溃疡愈合质量的方案.方法:采用分组对照的研究方法,并应用药物经济学方法分析各方案的费用与效果.初次根除Hp共115例,分为A、B、C、D 4组.A组为致康胶囊1次0.6g,4次/日,阿莫西林胶囊0.5g,4次/日,克拉霉素0.25g,2次/日,兰索拉唑30mg,2次/日;疗程为7天.B组为致康胶囊1次0.6g,4次/日.疗程为7天.C组为阿莫西林胶囊0.5g,4次/日,克拉霉素0.25g,2次/日,兰索拉唑30mg,2次/日;疗程为7天.D组为再次根除Hp共27例,方案同A组.疗程为7天.结果:A、B、C组的Hp根除率分别为93%、32%、94%,A、C组间无显著差异(P>0.05).D组根除率为81%.不良反应总发生率为16.2%,C组与A+D组或B组间有非常显著差异(P<0.01),A组与D组间无显著差异(P>0.05).治疗后1年,消化性溃疡发病率及Hp感染的变化,C组与A+D组或B组间有非常显著差异(P<0.01),A组与D组间无显著差异(P>0.05).治疗后1年消化性溃疡费用效益分析,边缘成本效益(IncrC/E)、成本效益(C/E)以A、C2组方案较优,A组方案最优.结论:加用致康胶囊能有效地改善治疗后1年消化性溃疡发病率及Hp感染率,不良反应少.治疗后1年费用效益分析,以A、C2组方案较优,A组方案最优.%Objective:To investigate effects and costs of Zhikang Capsule in combination with western Medicine for Helicobacter Pylori (Hp) to design rational corrective regimen for peptic ulcer. Methods:a grouped, pesitive-controlled study, and Pharmaco economics methods. Hp first eradicated patients( n = 115 ) were grouped and received respective treatments over a period of 7 days: group A received Zhikang Capsule 0. 6g Tid, Amoxicillin 0.5g Tid, Clarithromycin 0.25g Bid, Lansoprazo130mg Bid. Group B: Zhikang Capsule 0. 6g Tid. Group C: Group A minus Zhikang Capsule. Group D: 27 second eradiated patients, same regimen as group A. Results: eradicate rates for group A,B,C,D were respectively 93％ ,32％ ,94％ ,81％. Total AE rate = 16.2％. Differences between A and C, A and D were not significant (P ＞ 0. 05). Differences between C and ( A + D), C and B were significant ( P ＜ 0. 0l ). After 1 year of treatment, C and ( A + D), C and B were significantly different in terms of ulcer occurrence rate and Hp infection ( P ＜ 0. 01 ), A and D not significantly different (P ＞0.05) o In terms of CEA analysis (IncrC/E, C/E), A was the most cost effective, C was the second best. Conclusion: Zhikang Capsule, as an add-on treatment can reduce ulcer rate and Hp infection rate after 1-year treatment, and A is the most cost effective.
展开▼
